23andMe, a personal genetics company, has appointed Dean Schorno, CPA, as chief financial officer and head of operations. He will oversee 23andMe’s global financial and clinical laboratory operations. Schorno brings a wealth of experience to the job, most recently working as chief financial officer of Adaptive Biotechnologies.

As chief financial officer at Adaptive, Schorno led all financial operations, which included a significant financing and acquisition for the company. He also was responsible for laboratory operations and facilities management.

Prior to his role at Adaptive, Schorno spent 13 years at Genomic Health, where he was both vice president of operations and chief financial officer. During his tenure, he oversaw the launch and operations of Genomic Health’s clinical laboratory, as well as the company’s global financial affairs.